Dopamine Agonists Modify the Course of Parkinson Disease

Dopamine D3Receptor Agonist Delivery to a Model of Parkinson's Disease Restores the Nigrostriatal Pathway and Improves Locomotor Behavior

“…These drugs have been shown to modify the course of the disease, being associated with a reduced incidence of dyskinesias and motor fluctuations. Furthermore, recent evidence indicates that the advantages of ropinirole and pramipexole, two preferential dopamine D 3 receptor agonists used to treat PD, extend beyond purely symptomatic benefits (Stern, 2004). Indeed, using imaging markers of dopamine function, treatment with these agonists has been found to be associated with a reduction in disease progression (Parkinson Study Group, 2002;Whone et al, 2003).…”

Dopamine D3Receptor Agonist Delivery to a Model of Parkinson's Disease Restores the Nigrostriatal Pathway and Improves Locomotor Behavior

“…These drugs have been shown to modify the course of the disease, being associated with a reduced incidence of dyskinesias and motor fluctuations. Furthermore, recent evidence indicates that the advantages of ropinirole and pramipexole, two preferential dopamine D 3 receptor agonists used to treat PD, extend beyond purely symptomatic benefits (Stern, 2004). Indeed, using imaging markers of dopamine function, treatment with these agonists has been found to be associated with a reduction in disease progression (Parkinson Study Group, 2002;Whone et al, 2003).…”

Both Postsynaptic and Presynaptic Dysfunction Contribute to Parkinson Disease

“…2 More recently, the debate has centered around the notion that prolonged use of levodopa is somehow toxic to dopaminergic neurons while dopamine agonists are nontoxic and perhaps even protective. [3][4][5] Although framed very differently, these debates are not as unique as they might first appear, and key to all of the arguments is our evolving understanding of the pathophysiology of PD. While a debate about the relative importance of presynaptic 6 and postsynaptic 7 dysfunction to the evolution of PD may seem esoteric, improved understanding of its pathophysiology will help us to answer many long-debated issues.…”

Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson’s disease: a meta-analysis

“…Motor complications are seen less frequently with dopamine agonists or MAOBI than with L-dopa, suggesting that longer term symptomatic control could be better with Ldopa-sparing therapy than with L-dopa [5]. However, nonmotor side effects such as nausea, hallucinations, edema, and sleep disturbance are more common with dopamine agonists than with L-dopa, and could be more important for patients and caregivers than are motor complications [6]. Following this, attention focused on the possibility of using L-dopa-sparing therapy (dopamine agonists or MAOBI) as initial treatment for PD.…”

Dopamine D3Receptor Agonist Delivery to a Model of Parkinson's Disease Restores the Nigrostriatal Pathway and Improves Locomotor Behavior

“…These drugs have been shown to modify the course of the disease, being associated with a reduced incidence of dyskinesias and motor fluctuations. Furthermore, recent evidence indicates that the advantages of ropinirole and pramipexole, two preferential dopamine D 3 receptor agonists used to treat PD, extend beyond purely symptomatic benefits (Stern, 2004). Indeed, using imaging markers of dopamine function, treatment with these agonists has been found to be associated with a reduction in disease progression (Parkinson Study Group, 2002;Whone et al, 2003).…”

Both Postsynaptic and Presynaptic Dysfunction Contribute to Parkinson Disease

“…2 More recently, the debate has centered around the notion that prolonged use of levodopa is somehow toxic to dopaminergic neurons while dopamine agonists are nontoxic and perhaps even protective. [3][4][5] Although framed very differently, these debates are not as unique as they might first appear, and key to all of the arguments is our evolving understanding of the pathophysiology of PD. While a debate about the relative importance of presynaptic 6 and postsynaptic 7 dysfunction to the evolution of PD may seem esoteric, improved understanding of its pathophysiology will help us to answer many long-debated issues.…”

Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson’s disease: a meta-analysis

“…Motor complications are seen less frequently with dopamine agonists or MAOBI than with L-dopa, suggesting that longer term symptomatic control could be better with Ldopa-sparing therapy than with L-dopa [5]. However, nonmotor side effects such as nausea, hallucinations, edema, and sleep disturbance are more common with dopamine agonists than with L-dopa, and could be more important for patients and caregivers than are motor complications [6]. Following this, attention focused on the possibility of using L-dopa-sparing therapy (dopamine agonists or MAOBI) as initial treatment for PD.…”

Dopamine D3Receptor Agonist Delivery to a Model of Parkinson's Disease Restores the Nigrostriatal Pathway and Improves Locomotor Behavior

“…These drugs have been shown to modify the course of the disease, being associated with a reduced incidence of dyskinesias and motor fluctuations. Furthermore, recent evidence indicates that the advantages of ropinirole and pramipexole, two preferential dopamine D 3 receptor agonists used to treat PD, extend beyond purely symptomatic benefits (Stern, 2004). Indeed, using imaging markers of dopamine function, treatment with these agonists has been found to be associated with a reduction in disease progression (Parkinson Study Group, 2002;Whone et al, 2003).…”

Both Postsynaptic and Presynaptic Dysfunction Contribute to Parkinson Disease

“…2 More recently, the debate has centered around the notion that prolonged use of levodopa is somehow toxic to dopaminergic neurons while dopamine agonists are nontoxic and perhaps even protective. [3][4][5] Although framed very differently, these debates are not as unique as they might first appear, and key to all of the arguments is our evolving understanding of the pathophysiology of PD. While a debate about the relative importance of presynaptic 6 and postsynaptic 7 dysfunction to the evolution of PD may seem esoteric, improved understanding of its pathophysiology will help us to answer many long-debated issues.…”

Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson’s disease: a meta-analysis

“…Motor complications are seen less frequently with dopamine agonists or MAOBI than with L-dopa, suggesting that longer term symptomatic control could be better with Ldopa-sparing therapy than with L-dopa [5]. However, nonmotor side effects such as nausea, hallucinations, edema, and sleep disturbance are more common with dopamine agonists than with L-dopa, and could be more important for patients and caregivers than are motor complications [6]. Following this, attention focused on the possibility of using L-dopa-sparing therapy (dopamine agonists or MAOBI) as initial treatment for PD.…”